By Digifin Pty Ltd · About this coverage
Key Points
- Quarterly revenue of US$188k, up 437% on the prior corresponding period
- Rady Children's and Children's Medical Center Dallas became the first two U.S. customers
- Net loss of US$2.9m and net operating cash outflows of US$7.3m
- Cash of US$62.1m at 30 September 2026
- 14 of 15 FDA submissions for the full U.S. platform complete or under review
About Imricor (ASX:IMR)
Imricor Medical Systems, Inc. is an ASX-listed medical device company headquartered in Burnsville, Minnesota, in the United States. It develops and sells devices and capital equipment used to perform cardiac ablation procedures under real-time magnetic resonance imaging guidance.
Imricor (ASX:IMR) released its quarterly report and Form 10-Q for the quarter ended 30 September 2026, the quarter in which it began U.S. commercial sales of its NorthStar system to hospitals.
Figures are in US dollars. Rady Children's Hospital in San Diego became the first commercial U.S. hospital customer, and Children's Medical Center Dallas became the second two weeks after launch, which the company calls the first commercial outcome of a Philips compatibility declaration issued on 6 August 2026. Revenue was US$188k, up 437% on US$35k in Q3 CY2025, reflecting initial revenue from the first U.S. NorthStar sale; the Dallas installation occurred after quarter end, so that revenue will be recognised in Q4. Net loss was US$2.9m, down 17% from US$3.5m, and net operating cash outflows were US$7.3m, up from US$6.1m in Q2 CY2026, which the company attributes mainly to pre-paying annual insurance premiums. Cash was US$62.1m at 30 September 2026. FDA 510(k) clearances extended NorthStar and the Vision-MR Diagnostic Catheter to patients of all ages, and 14 of the 15 submissions for the full U.S. platform are now complete or under review. Imricor also launched Imricor Finance with DLL, under which hospitals pay over one to seven years while Imricor receives full payment upfront.
Final PMA approval for the Vision-MR Ablation Catheter still requires an FDA pre-approval inspection and a fourth module, to be submitted after the VISABL-AFL trial. The company says several more hospitals are in final purchasing stages, but the release does not name them.
Source: Imricor Medical Systems, Inc. (ASX:IMR), 13 November 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.